REPharma Summit 2024: ‘Reinvent, Restructure, and Reform’
Mumbai: The fourth edition of the RE-Pharma Summit 2024, organised by ETHealthworld and ETPharma, is gearing up for its fourth edition on January 20, 2024, at Courtyard by Marriott, Mumbai. This annual event will serve as a platform where policymakers and industry stalwarts such as Dr Rajeev Singh Raghuvanshi, Drug Controller General of India, Sudarshan Jain, Secretary General, Indian Pharmaceutical Alliance, Nikhil Chopra, CEO, JB Pharma, Kaushik Desai, Secretary General, International Pharmaceutical Excipients’ Council of India (IPEC India), Vikrant Shrotriya, Corporate Vice President & Managing Director, Novo Nordisk India Private Limited, Dr Anil Kukreja, Vice President – Medical Affairs and Regulatory AstraZeneca Pharma India Limited and stakeholders from the pharma sector will convene to deliberate on crucial matters in the Indian pharmaceutical sector and how India can climb up the chain of value creation. The theme of the conference is ‘Reinvent, Restructure, and Reform’. The Real Estate Partner for the RE-Pharma Summit 2024 is JLL, and the Supporting Partner is Bry-Air. The conference will bring together prominent figures in the pharma sector, and the summit’s fourth iteration promises to be a rich and informative gathering. The event will feature insights from policymakers, pioneering industry experts, pharma industry leaders and medical professionals who will share their perspectives on how the industry can move forward, build on value creation and innovate in India for Indians and the rest of the world.
The conference will commence with a welcome address by Prathiba Raju, Assistant Editor, Digital Content, ETHealthworld. This will be followed by the guest of honour address by Jitendra Kumar, Managing Director, BIRAC on ‘Navigating the Research and Funding Challenges of Biotech Startups in India’. Following the guest of honour address, there will be a partner presentation by JLL on ‘Transforming Spaces For Life Sciences’. The presentation will be delivered by Reji Samuel, Head, Lifesciences Advisory, India; Head – Office Leasing Advisory, Mumbai, JLL.
The partner presentation will be succeded by the ‘Inaugural Session: Volume-to-Value in the Indian Pharmaceutical Ecosystem’. The participants for the discussion will be Vikrant Shrotriya, Corporate Vice President & Managing Director, Novo Nordisk India Private Limited, Nikhil Chopra, CEO, JB Pharma, Sukanya Choudhury, Executive Vice President – Regulator, GlaxoSmithKline Pharmaceuticals. The moderator for the session will be Kaushik Desai, Secretary General, International Pharmaceutical Excipients’ Council of India (IPEC India).
The inaugural session will be followed by a panel discussion on ‘Deploying AI/ML for Drug Discovery & Biotechnology Innovations’. Dr Anil Kukreja, Vice President – Medical Affairs and Regulatory AstraZeneca Pharma India Limited, Narendra Saini, Chief Digital & Data Officer, Lupin, Dr Shubhadeep Sinha, Senior Vice President, Head, Clinical Development & Medical Affairs (CD&MA), Hetero Labs Limited, Dr Baskar Viswanathan Life Science, Business Consulting Officer, Agilisium will participate in the discussion. The session will be moderated by Dr Mukesh Kumar, Senior VP & Head Clinical R&D, Cipla.
The panel discussion will be succeeded by a fireside chat on ‘From Manufacturing to Patient’: Ensuring Seamless Pharma Supply Chains in India. The participants of the discussion will be Vishwanath Swarup, COO, India Business, Bharat Serums & Vaccines Ltd, Sabina Sawliwala, Chief Procurement Officer, Jaslok Hospital and Rohan Sharma, Director, Office Leasing Advisory, Bangalore & CRM Lead-Lifesciences, India, JLL. The session will be moderated by Chakravarthi AVPS Chairman, FOPE & AP and TS, President, INBA-Hyderabad & Honorary Advisor, Pharmexcil.
Post the fireside chat there will be a panel discussion on ‘Quality Metrics Transforming Pharma Manufacturing Practices’.Alok Mehrotra, Chief Quality Officer, Syngene International Limited, Shital Pathak, Sr VP – Head Analytical R&D (Formulations), Glenmark and Dr M Damodharan, Chief Quality Officer, Sai Life Sciences Limited will participate in the discussion. The session will be moderated by Sudarshan Jain, Secretary General, Indian Pharmaceutical Alliance.
Post the culmination of the panel discussion on ‘Quality Metrics Transforming Pharma Manufacturing Practices’. Dr Raghuvanshi will deliver the valedictory address. The event will conclude with the RE-Pharma Awards 2024.
Source – ETHealth World
